PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Idogen AB's interim report for January to September 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/
Second quarter (July-September 2022)Other operating income amounted to KSEK 0 (7,171)
Operating loss was KSEK -14,343 (-5,249)
Loss for the quarter totalled KSEK -14,398 (-5,191)
Cash flow from operating activities was KSEK -9,879 (-9,029)
Loss per share before dilution was SEK -0.20 (-0.28). Loss per share after dilution was SEK -0.20 (-0.28)
Other operating income amounted to KSEK 159 (10,580)
Operating loss was KSEK -36,212 (-25,413)
Loss for the quarter totalled KSEK -36,286 (-25,326)
Cash flow from operating activities was KSEK -38,111 (-25,116)
Loss per share before dilution was SEK -0.58 (-1.39). Loss per share after dilution was SEK -0.58 (-1.39)
Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London.
Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study with the IDO 8-program.
An extraordinary general meeting of shareholders on September 6 elected Joakim Söderström as new
- Christina Herder is appointed acting CEO after Anders Karlsson.
Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.
Idogens presented the company's tolerogenic cell therapy platform at the 5th Antigen-Specific Immune
Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from May 15.
Idogen's rights issue raise MSEK 41 after issue costs.
Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study
Idogen's rights issue raise MSEK 41 after issue costs.
Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.
Idogen strengthens the organization with key competencies for the clinical development phase.
Idogen's Idogen sharpens focus on its IDO 8 program, pauses the IDO T and IDO programs and lowers operating expenditure.
Idogen receives after exercise of warrants 280 KSEK before costs.
First patient enters Idogen's hemophilia study under the IDO 8 program.
EU to disburse the remaining of the Horizon 2020 grant.
Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors.
The board of Idogen propose a rights issue at up to 38 MSEK net after cost.
Idogen invites for an extra shareholder meeting 13 December
No other significant events occurred after the end of the period that affected the results or financial position.
For further information, please contact:
Christina Herder, Acting CEO, Idogen AB
Tel: +46 70374 71 56
E-mail: christina.herder@idogen.com
Certified Adviser:
Vator Securities AB
The information was submitted for publication, through the agency of the contact persons set out above, on November 25, 2022 at 08:03 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.